Casa
asdas

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Por um escritor misterioso

Descrição
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study, Arthritis Research & Therapy
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Baseline predictors of (A) ASDAS Major Improvement and (B) ASAS40 at
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Disease Control Data, Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study, Arthritis Research & Therapy
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Percentages of patients achieving ASDAS LDA (
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
PDF] ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Frontiers Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Full article: Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
AS Criteria: Diagnosis (ASAS), Disease Activity (ASDAS), Radiographic Progression (mSASSS) - Arthritis Rheumatism
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Axial Spondyloarthritis RINVOQ® (upadacitinib)
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Oral Abstracts - 2020 - International Journal of Rheumatic Diseases - Wiley Online Library
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Baseline characteristics of ASDAS ID and ASAS PR responders and
de por adulto (o preço varia de acordo com o tamanho do grupo)